Searched for
CARDIOLOGY TREATMENT OPTIONS
PE wars to billion-dollar IPO dreams, hospital sector is fighting fit- Time to take measured and logical risks? 5 small-caps from different sectors with upside potential of up to 26%
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 33%, according to analysts
- These large- mid- and small-cap stocks have an upside potential of up to 31% in 1 year, according to analystsAs nothing can be ruled out on the street, be prepared for anything. Now, what is the probability that the bears will be chased away from t...14 May, 2026, 11.51 PM IST
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 28%In these times of geopolitical stress, how will things pan out for the Indian market? Will it be a standalone underperformer? Or is it just...24 Apr, 2026, 10.18 PM IST
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 33%To get clarity on the markets, there are three questions to which you need answers. First: When will the war end? Second: How long will it ...20 Apr, 2026, 12.10 PM IST
- Novartis to acquire Avidity Biosciences for about $12 billionNovartis is acquiring U.S. biotech firm Avidity Biosciences for approximately $12 billion in cash to expand its rare disease treatment port...27 Oct, 2025, 06.26 AM IST
- Israel to launch world's first human spinal cord transplant using patient’s own cellsIsrael is set to perform the world’s first spinal cord transplant using a patient’s own cells, marking a historic milestone in regenerative...20 Aug, 2025, 10.22 PM IST
- Novartis offers payment plan for high-cost heart medicineNovartis introduces a financing scheme with Pine Labs for its cholesterol-lowering drug, Sybrava (inclisiran), in India, aiming to broaden ...27 May, 2025, 10.38 AM IST
- Novo Nordisk readies to bring weight-loss drug Wegovy to IndiaDanish pharmaceutical company Novo Nordisk is set to launch its anti-diabetes and weight-loss drug Wegovy in India, aiming to outperform El...07 Apr, 2025, 12.44 AM IST
- Broach Lifecare Hospital shares list at 90% premium over IPO priceBroach Lifecare Hospital shares listed on the BSE SME platform with a 90% premium on Wednesday, debuting at Rs 47.5 versus an issue price o...21 Aug, 2024, 10.10 AM IST
- Fosun Said to Mull Sale of India’s $3.6 Billion Gland PharmaA sale would help Gland’s Chinese owner raise cash as the once-acquisitive group seeks to shore up its balance sheet. Fosun International h...29 Nov, 2022, 04.53 PM IST
- Global scramble for Covid-19 cure injects new life into old drugsOver 20 anti-viral drugs that were discontinued from manufacturing or had research on them halted because of other priorities have now beco...26 Nov, 2020, 09.45 AM IST
- Buy Sun Pharmaceutical Industries, target Rs 581: Nirmal Bang Institutional EquitiesBuy Sun Pharmaceutical Industries at a price target of Rs 581.06 Mar, 2019, 05.33 PM IST
- 'India ranks among top 3 medical tourism destinations in Asia'India is known for cost-effective medical treatments along with high standards in cardiology, orthopaedics, nephrology, oncology and neuro ...01 Sep, 2014, 08.37 PM IST
- AstraZeneca's heart pill safe to use in ambulance but comes with no extra benefitBlood-thinning drug Brilinta by AstraZeneca is safe to use in ambulance but giving it early in provides no extra benefit.01 Sep, 2014, 12.50 PM IST
- Government to empanel 70 new hospitals, labs in Central Government Health SchemeAmong hospitals which exited citing delayed payments and recent rationalisation of CGHS rates are Balaji Action, Escorts and Max Hospital S...14 Apr, 2013, 04.18 PM IST
- Rel Life Sciences to focus on R&D, for nowThe company is all set to launch fifth biosimilar drug and seeks approvals for clinical trials and stem-cell treatment.13 Jul, 2010, 04.09 AM IST
- Ex-Satyam chief Raju in ICU after suffering chest painTainted Satyam founder B Ramalinga Raju was admitted to NIMS on Monday evening after he complained of chest pain.08 Sep, 2009, 02.51 AM IST
- Panel suggests Glaxo's Avandia can stayGlaxoSmithKline's shares surge after a panel of US doctors votes to keep the diabetes pill Avandia on the market.01 Aug, 2007, 02.35 AM IST
Load More
